Trenchant Technologies Capital Corp. News Releases

Trenchant Technologies Capital Corp. Completes Unwinding of Previous Limitless Quantum Acquisition and Corporate Updates

Wed, 22 Apr 2026 08:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - Trenchant Technologies Capital Corp. (CSE: AITT) (OTCQB: AITTF) ("Trenchant" or the "Company") announces that it has completed the unwinding of the Company's acquisition of Limitless Quantum Computing Solutions Inc. ("Limitless Quantum") (collectively, the "Unwinding Transaction"), as previously announced on April 8, 2026.The Company has effectively cancelled the 10,000,000 common shares of the Company (the "Trenchant Shares") and...

Trenchant Technologies Capital Corp. Announces Unwinding of Previous Limitless Quantum Acquisition

Wed, 08 Apr 2026 11:46:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 8, 2026) - Trenchant Technologies Capital Corp. (CSE: AITT) (OTCQB: AITTF) ("Trenchant" or the "Company") announces that it has entered into a share exchange agreement dated March 18, 2026 and fully executed on April 5, 2026, (the "Share Exchange Agreement") providing for the unwinding of the Company's previously announced acquisition of Limitless Quantum Computing Solutions Inc. ("Limitless Quantum") (collectively, the "Acquisition").As...

Trenchant Announces Closing of Non-Brokered Private Placement

Thu, 20 Jun 2024 22:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - Trenchant Technologies Capital Corp. (CSE: AITT) (OTC: AITTF) ("Trenchant" or the "Company") announces that, further to its News Release of June 12, 2024, it has completed its non-brokered private placement financing (the "Offering"), pursuant to which it has issued 400,000 units (each, a "Unit") for gross proceeds of $100,000. Each Unit consists of one common share (each, a "Share") and one common share purchase warrant (each, a...

GNQ Insilico's AI-Driven Digital Twin Platform Shows Promising Results in First Virtually Simulated Clinical Drug Trial

Tue, 18 Jun 2024 02:00:00 -0400

GNQ Insilico's ("GNQ") proprietary genomics-driven platform is leveraging Artificial Intelligence (AI) and Quantum Computing technologies to create "intelligent digital twins" of human patients that can mimic how a drug will interact with an individual patient's unique biology, down to the cellular level.GNQ's platform has demonstrated success in synthesizing digital twins of human patients.Additionally, GNQ was able to simulate the effects of a drug on these digital twins.The results highlight...

Trenchant Completes Initial Investment in GNQ Insilico Inc.

Wed, 01 May 2024 17:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Trenchant Capital Corp. (CSE: TCC) (the "Company") is pleased to announce that pursuant to an option agreement between the Company and GNQ Insilico Inc. ("GNQ") dated November 30, 2023, as amended from time to time ( the "Option Agreement"), it has acquired 20% of the total issued and outstanding common shares in the capital of GNQ (the "Initial Investment"). Concurrently with closing the Initial Investment, the Company entered into...

Trenchant Provides Update on Corporate Developments of and Investment in GNQ Insilico Inc.

Wed, 06 Mar 2024 09:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2024) - Trenchant Capital Corp. (CSE: TCC) (the "Company") announces that GNQ Insilico Inc. ("GNQ") has reported that it has commenced the development of an in silico clinical trial platform with a technology-based Fortune 100 company. On November 6, 2023, GNQ signed a Memorandum of Understanding with the Fortune 100 company to develop and commercialize an artificial intelligence (AI) driven drug development platform that integrates GNQ's...

Trenchant Announces Amendment to the Option Agreement and Closing of the First Tranche of Its Initial Investment in GNQ Insilico Inc.

Thu, 04 Jan 2024 09:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - January 4, 2024) - Trenchant Capital Corp. (CSE: TCC) (the "Company") is pleased to announce that it has entered into an amendment agreement (the "Amendment Agreement") to the previously announced option agreement between the Company and GNQ Insilico Inc. ("GNQ") dated November 30, 2023 (the "Original Option Agreement", and, together with the Amendment Agreement, the "Option Agreement"), pursuant to which the Company has closed the first tranche of...

Trenchant Announces Non-Brokered Private Placement

Tue, 05 Dec 2023 12:54:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - December 5, 2023) - Trenchant Capital Corp. (CSE: TCC) ("Trenchant" or the "Company") is pleased to announce that it intends to undertake a non-brokered private placement financing (the "Offering") consisting of the issuance of up to 10,000,000 units (each, a "Unit") at a price of $0.25 per Unit for gross proceeds of up to $2,500,000. Each Unit will consist of one common share (each, a "Share") and one transferable share purchase warrant (each, a...

Trenchant Announces Strategic Investment in GNQ Insilico Inc.

Fri, 01 Dec 2023 15:17:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - December 1, 2023) - Trenchant Capital Corp. (CSE: TCC) (the "Company") is pleased to announce that it has entered into a strategic investment with GNQ Insilico Inc. ("GNQ"), an Ontario-based company that is developing a generative artificial intelligence ("AI") and quantum computing platform to assist life sciences companies in conducting in silico clinical trials for drug discovery and drug development. The investment will be governed by terms of...